Prognostic Factors in Polycythemia Vera
Documenta Haematologica - Revista Romana de Hematologie · 23.06.2026 · 4 (2) · 67-72
DOI: 10.59854/dhrrh.2026.4.2.67 ↗Kurz gefasst
Fachartikel in der Zeitschrift Documenta Haematologica - Revista Romana de Hematologie, online erschienen am 23.06.2026. Verfasst von Sandor-Szilard PORTIK und 11 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction
Polycythemia vera is a chronic myeloproliferative neoplasm associated with an increased risk of thrombotic events, the main cause of morbidity and mortality. The established risk factors are age ≥60 years and prior thrombosis.
Objectives
To identify clinical, biological and therapeutic factors associated with thrombosis in PV patients. Materials and Methods: We conducted a retrospective, single-center study of 89 JAK+ PV patients diagnosed and treated between January 2015 and August 2025 in the Hematology Department of the “Prof. Dr. Ion Chiricuță” Institute of Oncology, Cluj-Napoca. Demographic, clinical, treatment-related and laboratory data (erythrocytes, hemoglobin, hematocrit, RDW, leukocytes, platelets, ferritin) were analyzed. Statistical evaluation was performed in GraphPad Prism using t-tests, Chi-square tests and logistic regression.
Results
The median age at diagnosis was 61,3 years; 50,5% were female. Comorbidities were present in 53,9%, most frequently arterial hypertension (47,9%). Thrombosis occurred in 19 patients (21,3%): 7 pre-diagnosis, 11 post-diagnosis and 1 both pre- and post-diagnosis, with an equal arterial/venous distribution. In univariate analysis, patients with thrombosis were older (66,63 vs. 59,91 years; p=0,039) and had higher RDW (53,57 vs. 49,17; p=0,007). Other factors (comorbidities, treatment) were not significantly associated with thrombosis. Multivariate regression identified RDW as the only independent predictor of thrombotic risk (HR=1,7; 95%CI: 1,06–4,2; p 0,005). Age and lower hematocrit showed trends (HR=1,04 and HR=0,62) without statistical significance.
Conclusion
RDW, a simple and affordable hematologic parameter, was independently associated with thrombotic risk in PV and may serve as an additional marker for thrombotic risk stratification.
Zitieren
APA
PORTIK, S., URIAN, L., ZDRENGHE, M., VASILACHE, A., TOROK, T., PARVU, A., TOMULEASA, C., DIMA, D., RUS, I., MESAROS, O., JIMBU, L., & BOJAN, A. (2026). Prognostic Factors in Polycythemia Vera. Documenta Haematologica - Revista Romana de Hematologie, 4(2), 67-72. https://doi.org/10.59854/dhrrh.2026.4.2.67
Vancouver
PORTIK S, URIAN L, ZDRENGHE M, VASILACHE A, TOROK T, PARVU A, et al. Prognostic Factors in Polycythemia Vera. Documenta Haematologica - Revista Romana de Hematologie. 2026;4(2):67-72. doi:10.59854/dhrrh.2026.4.2.67
BibTeX
@article{PORTIK2026,
author = {PORTIK, Sandor-Szilard and URIAN, Laura and ZDRENGHE, Mihnea and VASILACHE, Anca and TOROK, Tunde and PARVU, Andrada and TOMULEASA, Ciprian and DIMA, Delia and RUS, Ioana and MESAROS, Oana and JIMBU, Laura and BOJAN, Anca},
title = {Prognostic Factors in Polycythemia Vera},
journal = {Documenta Haematologica - Revista Romana de Hematologie},
year = {2026},
volume = {4},
number = {2},
pages = {67--72},
doi = {10.59854/dhrrh.2026.4.2.67}
}
EUVIMED